Novo Nordisk A/S Class B (NOVOBc)

733.00
-15.65(-2.11%)
  • Volume:
    472,929
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    721.75 - 735.48
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0060534915

NOVOBc Overview

Prev. Close
741.85
Day's Range
721.75-735.48
Revenue
-
Open
730.4
52 wk Range
433.7-830.05
EPS
-
Volume
472,929
Market Cap
1.67T
Dividend (Yield)
10.40
(1.41%)
Average Vol. (3m)
506,089
P/E Ratio
-
Beta
-
1-Year Change
52.31%
Shares Outstanding
2,271,511,119
Next Earnings Date
Aug 04, 2022
What is your sentiment on Novo Nordisk B?
or
Market is currently closed. Voting is open during market hours.

Novo Nordisk A/S Class B News

Novo Nordisk A/S Class B Analysis

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S Class B Company Profile

Employees
46982
Market
Denmark

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellSellBuy
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Buy
SummaryBuyNeutralStrong SellStrong SellStrong Buy
  • Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
    0
    • New Target 825 by EOM
      0
      • New Target 825
        0
        • Consolidating nicely for leg up to 850!🌟
          0
          • Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
            1
            • Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
              0
              • bullish??
                0
                • No. Funds are selling. Time to wait to go long...
                  0
              • Perfect opportunity to make short,,
                1
                • can you explain why please?
                  0
                • No explaning? 🤷
                  0
                • because he has no explanation. Novo nordisk is a soli long-term stock. I know a lot about opioid treatments, and methadon is changing to lipo-methadon, wich has really only one competitor on the global field. That competitor is Camurus AB with their product buvidol. I tecommend to all investors to buy and HOLD for these two companies, because there is no other options for a opioid-replacement-care, except Suboxone, and that is going to be replaced Lipo-methadon or Buvidol, at least here in Finland. Suboxone is manufactured for Indivor Inc, by Aquestive Therapeutics, if someone wants to do a little research.
                  0
              • Bullish sentiment.
                0
                • Why is going so low???
                  0